CLLS: נכסי החברה Cellectis S.A.

Cellectis S.A. (CLLS) generates revenue by licensing unique genome modification methods to combat hematological tumors in partnership with global pharma behemoths. The market dynamics of total assets on GURU.Markets, as reflected in the price action, stand at 310.65, confirming the company's status as a pioneer in creating accessible "off-the-shelf" TALEN-based therapies. Business development relies on a strategic alliance with AstraZeneca and strict FDA oversight within an innovative ecosystem.

Cellectis S.A. (CLLS) maintains its status as a gene editing leader, allowing the company to capitalize on unique platforms through high-cost licenses. This indicator reflects the total value of resources and liabilities, calculated inversely via return on assets (ROA). Monitoring this metric helps assess capital management efficiency while scaling biopharmaceutical developments. The trend in consolidated asset volume clearly demonstrates the expansion rate of the company's material base.